In the phase 3 LIBERTY-CSU CUPID-C randomized clinical trial and pooled analyses of CUPID-A and CUPID-C, dupilumab significantly reduced itch severity and overall urticaria activity compared with placebo in patients with chronic spontaneous urticaria who remained symptomatic despite histamine 1–receptor antagonist therapy and had not previously received anti–immunoglobulin E treatment. Improvements in Itch Severity Score and Urticaria Activity Score were evident by week 24, with a higher proportion of dupilumab-treated patients achieving well-controlled or complete symptom resolution, and safety outcomes were consistent with the drug’s established profile.

Source: JAMA Dermatology